首页> 外文期刊>Current respiratory medicine reviews >Management of connective tissue interstitial lung disease
【24h】

Management of connective tissue interstitial lung disease

机译:结缔组织间质性肺疾病的管理

获取原文
获取原文并翻译 | 示例
       

摘要

The connective tissue diseases (CTD) are frequently associated with Interestitial lung diseases (ILD). The presence of an ILD in a patient with CTD is associated with a higher morbidity and mortality. Management of a patient with connective tissue interstitial lung disease (CTD-ILD) depends on disease severity with a focus on improving quality of life. Therapeutic interventions include medications, which aim to prevent progression to fibrosis and decrease inflammation or alveolitis, supplemental oxygen; and pulmonary rehabilitation. Comorbidities including gastroesophageal reflux disease (GERD) and obstructive sleep apnea should be addressed in all CTD-ILD patients. Appropriate referral to support groups, lung transplantation centers, and palliative care are considerations for all patients with CTDILD. The management of a patient with CTD-ILD is a multidisciplinary personalized process that is driven by the specific disease, clinical pattern, and associated comorbidities.
机译:结缔组织疾病(CTD)经常与兴趣性肺部疾病(ILD)相关。 CTD患者中ILD的存在与较高的发病率和死亡率相关。患有结缔组织间质性肺病(CTD-ILD)的患者的治疗取决于疾病的严重程度,重点是改善生活质量。治疗干预措施包括药物,其目的是防止纤维化进展并减少炎症或肺泡炎,补充氧气;和肺康复。所有CTD-ILD患者均应解决合并症,包括胃食管反流病(GERD)和阻塞性睡眠呼吸暂停。所有CTDILD患者均应考虑适当转诊至支持组,肺移植中心和姑息治疗。 CTD-ILD患者的治疗是一个多学科的个性化过程,受特定疾病,临床模式和相关合并症的驱动。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号